CLINUVEL has announced that Health Canada has granted a Notice of Compliance allowing SCENESSE to be marketed in the country for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria, a rare metabolic disorder that causes debilitating phototoxic reactions and burns after brief exposure to visible light. …
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 Australian Biotech
Latest Video
New Stories
-
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News -
Achieving value is meaningless if it undermines access to medicines
August 10, 2026 - - Latest News -
New Zealand's ACT announces plan for pharmacies to do a lot more, but also ownership and location reform
August 10, 2026 - - Latest News -
France the first to provide comprehensive reimbursement for GLP-1s for weight loss while Australia looks on
August 10, 2026 - - Latest News